Premium
GST‐7T and P‐170 co‐expression in multiple myeloma
Author(s) -
PETRINI MARIO,
SIMONE DANIELA DI,
FAVATI ADRIANA,
MATTII LETIZIA,
VALENTINI PAOLA,
GRASSI BRUNO
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05164.x
Subject(s) - multiple myeloma , plasma cell myeloma , p glycoprotein , bone marrow , medicine , glutathione s transferase , glutathione , microbiology and biotechnology , immunology , drug resistance , biology , cancer research , pathology , enzyme , multiple drug resistance , biochemistry , genetics
Summary. Bone marrow samples from 40 patients affected by multiple myeloma either treated or untreated were examined for expression of glutathione‐S‐transferase n (GST‐TT), P‐glycoprotein and the protein product of ras oncogenes family, p‐21, on plasma cells, by immuno‐cytochemical detection. 72% of evaluated samples were positive for P‐170 and 82% for GST‐7T without any correlation with clinical or prognostic parameters. A significant relationship between GST‐7T expression and P‐l 70 positivity was found and co‐expression was observed in 91% of evaluated samples. Expression of P‐170 and GST‐TT was found both in treated and untreated patients. However, patients evaluated before and after therapy showed an increase in the percentage of plasma cells positive for GST‐7T or P‐170 or both. Expression of p‐21 was not associated with these mechanisms of drug resistance. These data suggest that different resistance mechanisms are present in multiple myeloma.